Cases in detail
1. + 2. There is no risk of YF infection for wife and husband. For the wife's transit, no vaccination or exemption is necessary. The husband needs YFV or an exemption certificate, depending on the availability of YFV. Independent of YFV availability, 60% of the specialists decided not to immunise the wife. More than 35% favoured an exemption in case of vaccine shortage or would have vaccinated. In case of vaccination, the wife would have been exposed to an unnecessary risk, especially, as persons aged 60 years and above have an increased risk of YEL-AVD [5] . For the husband, almost 90% opted for vaccination in scenario (i.) and around 70% for an exemption in scenario (ii.), i.e., a majority chose the correct answer according to current recommendations.
3.
During pregnancy, YFV is generally not recommended although teratogenic effects have not been described [6] . The decision on vaccination during pregnancy has to be taken after an individual risk/ benefit assessment [7] . As São Paulo and Rio de Janeiro are YF free and Iguaçu has a very low YF endemicity [8] , the correct approach according to Swiss recommendations would be to abstain from YFV, in both vaccine availability scenarios. As YFV is not mandatory for a trip to Brazil, an exemption certificate is unnecessary. Around 60% of respondents decided not to immunise in both scenarios; still more than a third opted for an unneeded exemption. Although not harmful, it brings along additional costs for the traveller as well as unnecessary workload.
4.
As Cameroon has a moderate YF endemicity [8] , Swiss recommendations would rather favour YFV in this pregnant woman regardless of vaccine availability depending on her destination within Cameroon. However, this decision might be arguable. Around 40% of specialists decided to vaccinate in both scenarios. A larger group opted for an exemption. Still, in case of sufficient vaccine supplies, 5% chose not to vaccinate without handing out an exemption. This decision may cause problems, as YFV is mandatory for entering Cameroon.
5.
The traveller is not exposed to YF during this trip, but Thailand requires YFV when entry occurs within 10 days after visiting an endemic country. In the case of sufficient vaccine supplies, YFV is recommended; otherwise an exemption should be issued.
More than 90% correctly decided to vaccinate the traveller in scenario (i); in scenario (ii), half of the respondents correctly opted for an exemption. In both scenarios, some specialists decided neither to vaccinate nor to exempt, leaving the traveller at risk of not being able to enter Thailand. 6.
YFV is contraindicated under azathioprine/ 6-mercaptopurine [9] . Also, issuing an exemption is not recommended owing to the high YF infection risk; hence, this trip should not be undertaken.
In both scenarios, around 70% would have issued an exemption. However, it is alarming that more than 20% decided to vaccinate endangering the immunosuppressed traveller due to the replication capacity of the attenuated vaccine strain. A minority would have not vaccinated without issuing an exemption. 7.
According to 2013 WHO recommendations, a single YFV dose provides lifelong protection [7] , even if a person started immunosuppressive medication afterwards. Therefore, an exemption should be issued to enter Ethiopia, as YFV is mandatory coming from an YF endemic country. A majority chose the correct answer; however, more than a quarter decided not to issue an exemption despite Ethiopian regulations. In scenario (i), 10% of experts would have given YFV even though it is clearly contraindicated under immunosuppression [9] .
8. This traveller is still protected from the vaccine dose he received in 1973 according to WHO recommendations [7] . According to entry regulations, neither vaccination nor exemption is necessary if entering Kenya directly from Europe. Around 20% responded to vaccinate the traveller in scenario (i), although unnecessary by new WHO recommendations [7] . In our survey, delay or cancellation of a trip or interrupting immunosuppressive medication was not an option; however, in real life this will sometimes (but not always!) be a solution, as was also indicated by several comments on the questionnaires. Overall, we saw that even among experts in a country with one of the highest travel frequencies, great uncertainty exists regarding the indication for YFV. Partly, these disagreements or uncertainties are provoked by the new WHO recommendations as well as conflicting border regulations. The Strategic Advisory Group of Experts on Immunization of the WHO stated in May 2013 that a single YFV dose confers lifelong protection (opposed to the previous 10-year recommendation). This decision is still viewed with scepticism among experts [10, 11] as studies looking at long-term immunity after YFV show conflicting results (table 1 in Ref. [12] ). Furthermore, many countries have not adapted their border policies consistently. Thus, travel health practitioners find themselves in a conflicting situation between current WHO recommendations and official country regulations, further complicated by constantly changing country-specific entry requirements. Currently, if in doubt, YFV is often administered rather than risking the traveller being denied entry into a country. However, it is assumed that all countries will respect the new recommendations of lifelong protection after YFV in due time. 
